Featuring an interview with Dr Erica Mayer, including the following topics:

• Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
• Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
• Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)
• Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)
• Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)
• Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)
• Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)
• Investigator Survey Results on Adjuvant Oral SERDs (43:02)
• Discussion of Questions from the Community (45:00)

CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

• Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
• Managing brain metastases in triple-negative breast cancer (6:30)
• EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)
• PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)

CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

• Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
• First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
• First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)
• Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)

CME information and select publications